ArticleBrain and behavior2026
Glycyrrhizic Acid Relieves Fatigue Induced by Acute and Chronic Exercise in Mice via Inhibition of the NF-κB/NLRP3 Signaling Pathway.
Article in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundGlycyrrhizic acid (Gly-A) exhibits anti-inflammatory and antioxidant effects in various central nervous system disorders. Acute fatigue and chronic fatigue (CF) are associated with serious physical and psychological effects. However, the underlying pathophysiology and effective therapeutic strategies for these conditions remain poorly understood. PURPOSE: This study aims to evaluate the therapeutic potential of Gly-A against fatigue, and to elucidate the underlying mechanisms of its action.
methodsWe established a mouse model of acute exercise-induced fatigue and evaluated fatigue-related indices. To identify specific pathways involved in Gly-A's therapeutic effects, we employed RNA sequencing, network pharmacology, and in vitro oxygen-deficit models, aiming to clarify the mechanisms. Additionally, we established a mouse model of CF to compare the therapeutic efficacy of Gly-A with positive control drugs by assessing identical parameters.
resultsGly-A significantly improved fatigue-related indices without affecting body weight. RNA sequencing and network pharmacology analyses showed that Gly-A modulates oxidative stress responses and targets the NF-κB (nuclear factor-kappa B)/NLRP3 (NOD-like receptor thermal protein domain associated protein 3) signaling and apoptotic pathways. In the CF mouse model, oral administration of Gly-A significantly increased motor activity, alleviated anxiety and depression, and improved neurocognitive function compared to model mice, exhibiting superior efficacy to positive control drugs. These findings suggest that Gly-A exerts anti-inflammatory effects by targeting the NF-κB/NLRP3 signaling pathway, thereby reducing neuronal apoptosis in CF.
conclusionsGly-A exhibits therapeutic potential against acute exercise-fatigue and CF, primarily by attenuating apoptosis through the inhibition of the NF-κB/NLRP3 signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.